At the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda, integration with the wider healthcare system was widely presented as a practical response to ...

“Lenacapavir is a product with real transformational potential that has the power to change the history of HIV,” Carolyn Amole of the Clinton Health Access Initiative (CHAI) told last week’s 13th ...

Artificial intelligence (AI) featured prominently at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda last week. Experts expressed excitement – and some ...

A high-level panel discussion convened at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda drew together representatives from global funding foundations, ...

More than half of people who received a pair of broadly neutralising antibodies (bnAbs) plus the immune-modulating drug N-803 (Anktiva) had delayed viral rebound or maintained a low or suppressed ...

Garnering a standing ovation at IAS 2025, Sameer Sah, from Medical Aid for Palestinians, provided a devastating first-hand account of what’s been happening for nearly two years in Gazan healthcare ...

Cuts in US funding for HIV programmes have already led to declines in testing and treatment starts in several countries, research presented last week at the 13th International AIDS Society ...

New data presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) yesterday show that two long-acting injectable PrEP options, lenacapavir and cabotegravir, are safe, well ...

Two studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco last week found that so far relatively few people with HIV are taking ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...